Key Highlights

• Thermo Fisher's $0.47 quarterly Dividend trades ex-date and Record Date September 15, 2026, payable October 15, yielding approximately 0.31%.

• Second-quarter Revenue grew 10% to $11.99 billion, with adjusted EPS up 13% to $6.03, both ahead of prior guidance.

• The company repurchased approximately $1 billion of stock in the quarter and raised full-year 2026 guidance on both revenue and EPS.

• A pending divestiture of the microbiology Business is expected to close in the third quarter.

Thermo Fisher Scientific's (NYSE:TMO) $0.47 quarterly dividend trades ex-date and record date September 15, payable October 15. Revenue reached $11.99 billion, roughly $300 million ahead of prior guidance, with adjusted EPS of $6.03 exceeding guidance by $0.30, while the pending microbiology-business divestiture is expected to trim approximately $200 million of 2026 revenue.

Dividend Program and Shareholder Returns

Thermo Fisher declared a $0.47 per share quarterly dividend, payable October 15 to shareholders of record and ex-dividend date September 15. The annualized dividend is $1.88 per share, up from $1.72 in 2025. The company repurchased approximately $1 billion of stock during the quarter.

About the Company

Thermo Fisher is one of the world's largest providers of laboratory equipment, analytical instruments, reagents, consumables and outsourced pharmaceutical services.

Financial Performance Behind the Payout

Thermo Fisher reported second-quarter revenue of $11.99 billion, up 10% year over year, including 5% organic growth, roughly $300 million ahead of prior guidance. GAAP diluted EPS was $4.68, up 9%, while adjusted EPS was $6.03, up 13% and $0.30 ahead of prior guidance. Adjusted Operating Income grew 15% to $2.73 billion, with adjusted Operating Margin expanding 90 basis points to 22.8%. Management raised full-year 2026 guidance to revenue of $47.4-$48.1 billion and adjusted EPS of $24.93-$25.33. The pending divestiture of the microbiology business, expected to close in the third quarter, is expected to trim roughly $200 million of 2026 revenue and $0.05 of adjusted EPS.

Outlook

Continued Clario integration and revenue-synergy realization, the completion and financial impact of the microbiology divestiture, and whether raised full-year guidance holds through the back half of 2026 are the items management has flagged for tracking.